Alprazolam Tablets 0.5 mg Recalled Due to cGMP Deviations
ANI Pharmaceuticals is voluntarily recalling Alprazolam Tablets USP 0.5 mg in multiple package sizes nationwide due to cGMP (current Good Manufacturing Practice) deviations. The recall affects approximately 205,662 bottles distributed across the United States.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall initiated voluntarily by the manufacturer for cGMP deviations. The source text does not report any illnesses, injuries, or deaths associated with the product. The recall is precautionary in nature based on manufacturing process deviations rather than demonstrated harm.
Plain-English summary
ANI Pharmaceuticals, Inc. is voluntarily recalling Alprazolam Tablets, USP 0.5 mg in three package sizes: 100-count bottles (NDC 67253-901-10), 500-count bottles (NDC 67253-901-50), and 1000-count bottles (NDC 67253-901-11). All packages are marked "Rx only" and were distributed by Par Pharmaceutical of Chestnut Ridge, New York.
The recall was initiated due to cGMP (current Good Manufacturing Practice) deviations identified in the manufacturing process. Approximately 205,662 bottles have been distributed nationwide within the United States. Specific lot numbers and expiration dates affected by this recall are detailed in the recall notice.
Consumers and healthcare providers with affected bottles should stop use and consult with a healthcare professional or pharmacist before discontinuing this medication. Patients should not stop taking alprazolam without medical guidance due to potential withdrawal effects. The affected lot numbers and expiration dates can be verified through the FDA recall notice or by contacting ANI Pharmaceuticals.
The recalled product
- Product
- Alprazolam Tablets, USP 0.5 mg, packaged in a) 100-count bottles (NDC 67253-901-10), b) 500-count bottles (NDC 67253-901-50), and c) 1000-count bottles (NDC 67253-901-11), Rx only, Distributed by: Par Pharmaceutical Chestnut Ridge, NY 10977
- Manufacturer
- ANI Pharmaceuticals, Inc.
- Hazard
- Affected units
- 205,662
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: a) 19B029A
- Exp. Date 02/2022
- 19D021A
- Exp. Date 04/2022. b) 19A087B
- 19A088B
- 19A089B
- 19A090B
- 19A086B
- 19A091B
- 19B019B
- Exp. Date 02/2022. c) 19B020C
- 19B021C
- 19B027C
- 19B028C
- 19E056C
- 19E057C
- Exp. Date 05/2022
- 19E059C
- Exp. Date 06/2022 19G072C
- Exp. Date 07/2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 5 recalled by ANI Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same manufacturer · ANI Pharmaceuticals, Inc.
See all →- LowHydroxyzine Hydrochloride Oral Solution recalled for foreign substance
FDA (Drugs) · 2026-07-01
- ModerateEstradiol Gel Packets Recalled for Empty or Partially Full Containers
FDA (Drugs) · 2026-05-27
- ModerateAlprazolam Tablets 2.0 mg Recalled for cGMP Deviations
FDA (Drugs) · 2022-02-23
- ModerateAlprazolam Tablets USP 1.0 mg Recalled for cGMP Deviations
FDA (Drugs) · 2022-02-23
- ModerateAlprazolam Tablets USP 0.25 mg Recalled for cGMP Deviations
FDA (Drugs) · 2022-02-23
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09